PubMed Health⌕ Search

Biomedical subjects

N R Bergquist

Publications and source records attributed to N R Bergquist.

32 records · Page 2Linked to original sources
PubMed1976

Antibodies to calf serum as a cause of unwanted reaction in immunofluorescence tests.

One potentially important cause of disturbing staining of cell cultures used for immunofluorescence (IF) tests was found to be a specific reaction between calf serum and corresponding antibodies. A simple method utilizing polymerized calf serum as an immunosorbent was used for the removal of the antibodies causing the undesired reactions. One to three cycles of absorption with the calf serum immunosorbent were highly efficient in removing antibodies to calf serum, whereas the titer of a heterologous antiserum (anti-egg albumin) was only slightly affected by the same procedure. An enzyme linked immunosorbent assay (ELISA) was used for determination of the efficacy of the absorption method.

Absorption↗
PubMed1975

Laser excitation of fluorescent copolymerized immunoglobulin beads.

A pulsed laser microfluorometric system is a practical proposition. The narrow line of excitation makes filter quality less important. Because bleaching does not occur, reliable measurements and reexcitation of preparations for control purposes are feasible.

Antibodies, Anti-Idiotypic↗
PubMedDate not supplied

Schistosomiasis vaccine development: approaches and prospects.

Mounting evidence for acquired immunity to schistosomiasis in humans supports the case for immunological intervention. On the other hand, rapid reinfection poses a threat to younger age groups due to the slow maturation of natural resistance. However, rational approaches, based on advances in immunology and molecular biology, have substantially increased the odds of producing an effective vaccine. Since the parasite cannot replicate in the human host and serious morbidity generally occurs only after a relatively long period of heavy worm burden, complete protection against infection is not essential. The chances of success would increase if more than one of the various host/parasite interphases were targeted, for example reducing morbidity through decreased worm loads as well as through suppression of egg production. Several promising schistosome antigens have now reached an advanced phase of development and are currently undergoing independent confirmatory testing according to a standardized protocol. A few molecules are being contemplated for scaled-up production but, so far, only one has reached the stage of industrial manufacture and safety testing. Since schistosomiasis cannot realistically be controlled by a single approach, vaccination is envisaged to be implemented in conjunction with other means of control, notably chemotherapy.

Adolescent↗